ALLO Stock Annual Cash Flow. Download in Excel
Allogene Therapeutics Inc.
ALLO 
NGS
Sector: Healthcare
Industry: Biotechnology
1.42
USD
0.13
(10.08%)
Previous close: 1.29 Open: 1.3 Bid: 1.4 Ask: 1.43
52 week range
0.86 3.78
Mkt Cap: 295 M Avg Vol (90 Days): 3,337,591
Last updated: Sunday 8th June 2025
Financials
ALLO Cash Flow
Annual
| Invalid date | Dec-18 | Dec-19 | Dec-20 | Dec-21 | Dec-22 | Dec-23 | Dec-24 | |
|---|---|---|---|---|---|---|---|---|
| (Increase) Decrease in other current assets | -244000.0 | -4 M | 34000.0 | |||||
| (Increase) Decrease in other current liabilities | -2 M | 39 M | -39 M | -21000.0 | -3000.0 | |||
| (Increase) Decrease in other working capital | -7 M | -1 M | 396000.0 | -5 M | -2 M | 5 M | ||
| (Increase) Decrease in payables | 9 M | -985000.0 | 615000.0 | -767000.0 | 5 M | -8 M | -503000.0 | |
| Acquisitions | -5 M | -18 M | ||||||
| Amortization of intangibles | 452000.0 | 603000.0 | 151000.0 | |||||
| AssetImpairmentCharge | 20 M | 18 M | ||||||
| CapitalExpenditureReported | 3 M | 51 M | 66 M | 21 M | 5 M | 2 M | 694000.0 | |
| Cash at beginning of period | 94 M | 179 M | 193 M | 184 M | ||||
| Cash at end of period | 94 M | 179 M | 193 M | 184 M | 72 M | -234 M | 86 M | |
| Cash flow | -45 M | -137 M | -115 M | -185 M | -221 M | -238 M | -200 M | |
| CashFlowFromContinuingInvestingActivities | -633 M | 164 M | -505 M | 164 M | 106 M | 163 M | 76 M | |
| ChangeInAccountPayable | 9 M | -985000.0 | 615000.0 | -767000.0 | 5 M | -8 M | -503000.0 | |
| ChangeInAccruedExpense | 12 M | 6 M | 19 M | 4 M | 2 M | -7 M | -1 M | |
| ChangeInInterestPayable | 12 M | 6 M | 19 M | |||||
| ChangeInPayablesAndAccruedExpense | 21 M | 5 M | 19 M | 3 M | 7 M | -14 M | -2 M | |
| ChangeInPrepaidAssets | -9 M | -5 M | -3 M | 3 M | 3 M | 1 M | -21 M | |
| ChangeInWorkingCapital | 12 M | -7 M | 54 M | -32 M | 4 M | -15 M | -18 M | |
| Current deferred income taxes | -331000.0 | 443000.0 | ||||||
| Deferred income taxes | -331000.0 | 443000.0 | ||||||
| Depreciation | 1 M | 4 M | 7 M | 10 M | 14 M | 14 M | 14 M | |
| Depreciation unreconciled | 5 M | 5 M | 8 M | 10 M | 14 M | 14 M | 14 M | |
| DepreciationAndAmortization | 5 M | 5 M | 8 M | 10 M | 14 M | 14 M | 14 M | |
| EarningsLossesFromEquityInvestments | 11 M | 2 M | ||||||
| FinancingCashFlow | 771 M | 59 M | 634 M | 12 M | 3 M | 96 M | 117 M | |
| Free cash flow | -48 M | -188 M | -181 M | -206 M | -226 M | -239 M | -201 M | |
| GainLossOnInvestmentSecurities | -4 M | 3 M | 7 M | 3 M | -7 M | -8 M | ||
| Issuance of capital stock | 344 M | 56 M | 599 M | 4 M | 2 M | |||
| IssuanceOfCapitalStock | 344 M | 56 M | 599 M | 4 M | 2 M | |||
| IssuanceOfDebt | 117 M | |||||||
| Net cash from financing activities | 771 M | 59 M | 634 M | 12 M | 3 M | 96 M | 117 M | |
| Net cash from investing activities | -633 M | 164 M | -505 M | 164 M | 106 M | 163 M | 76 M | |
| Net cash from operating activities | -45 M | -137 M | -115 M | -185 M | -221 M | -238 M | -200 M | |
| Net change in cash & cash equivalents | 94 M | 86 M | 13 M | -9 M | -111 M | 21 M | -8 M | |
| Net income from continuing operations | -212 M | -185 M | -250 M | -257 M | -340 M | -327 M | -258 M | |
| NetBusinessPurchaseAndSale | -5 M | -18 M | ||||||
| NetCommonStockIssuance | 344 M | 56 M | 599 M | 4 M | 2 M | |||
| NetInvestmentPropertiesPurchaseAndSale | -630 M | 220 M | -439 M | 203 M | 111 M | 6 M | 5 M | |
| NetInvestmentPurchaseAndSale | -630 M | 220 M | -439 M | 203 M | 111 M | 6 M | 5 M | |
| NetIssuancePaymentsOfDebt | 117 M | |||||||
| NetLongTermDebtIssuance | 117 M | |||||||
| NetPPEPurchaseAndSale | -3 M | -51 M | -66 M | -21 M | -5 M | -2 M | -694000.0 | |
| NetPreferredStockIssuance | 299 M | |||||||
| Operating (gains) losses | -4 M | 3 M | 10 M | 5 M | 11 M | -1 M | ||
| Other financing charges net | 11 M | 26 M | ||||||
| Other investing changes net | -2 M | |||||||
| Other non-cash items | 148 M | 46 M | 70 M | 84 M | 96 M | 80 M | 63 M | |
| PreferredStockIssuance | 299 M | |||||||
| ProceedsFromStockOptionExercised | 11 M | 3 M | 9 M | 8 M | 489000.0 | |||
| Purchase of Float term investments | -649 M | -253 M | -1,038 M | -526 M | -248 M | |||
| Purchase of property plant & equipment | -3 M | -51 M | -66 M | -21 M | -5 M | -2 M | -694000.0 | |
| Purchase of short term investments | 117 M | |||||||
| PurchaseOfInvestment | -649 M | -253 M | -1,038 M | -526 M | -248 M | |||
| PurchaseOfPPE | -3 M | -51 M | -66 M | -21 M | -5 M | -2 M | -694000.0 | |
| Revenue per share | 4 M | 603000.0 | 151000.0 | |||||
| Sale of Float term investments | 22 M | 473 M | 598 M | 728 M | 359 M | |||
| Sale of short term investments | 359 M | 6 M | 5 M | |||||
| SaleOfInvestment | 22 M | 473 M | 598 M | 728 M | 359 M | 6 M | 5 M | |
| StockBasedCompensation | 19 M | 46 M | 65 M | 81 M | 84 M | 66 M | 52 M |
Call: 1-877-778-8358 
Welcome! I'm Ankur, the founder and CEO of MarketXLS. With more than ten years of experience, I have assisted over 2,500 customers in developing personalized investment research strategies and monitoring systems using Excel.
I invite you to book a demo with me or my team to save time, enhance your investment research, and streamline your workflows.
I invite you to book a demo with me or my team to save time, enhance your investment research, and streamline your workflows.
Implement "your own" investment strategies in Excel with thousands of MarketXLS functions and templates.
MarketXLS provides all the tools I need for in-depth stock analysis. It's user-friendly and constantly improving. A must-have for serious investors.
I have been using MarketXLS for the last 6+ years and they really enhanced the product every year and now in the journey of bringing in AI...
MarketXLS is a powerful tool for financial modeling. It integrates seamlessly with Excel and provides real-time data.
I have used lots of stock and option information services. This is the only one which gives me what I need inside Excel.